

ENDOCANNABINOIDS AND SKELETAL MUSCLE GLUCOSE UPTAKE

A Thesis Submitted by

Paul Cavuoto

For the Degree of

Doctor of Philosophy

Discipline of Medicine

University of Adelaide

December 2010

TABLE OF CONTENTS

TABLE OF CONTENTS.....	ii
LIST OF FIGURES AND TABLES	vi
THESIS SUMMARY.....	ix
THESIS DECLARATION.....	xiii
ACKNOWLEDGEMENTS	xiv
PUBLICATIONS ARISING FROM THIS THESIS.....	xviii
CONFERENCE PRESENTATIONS.....	xx
LIST OF ABBREVIATIONS	xxiii
BACKGROUND.....	1
1.1. INTRODUCTION.....	1
1.2. SKELETAL MUSCLE	3
1.2.1. Skeletal Muscle Glucose Metabolism	3
1.2.2. Glucose Disposal in Skeletal Muscle	7
1.2.3. Intracellular Mechanisms Mediating Skeletal Muscle Glucose Utilisation	10
1.3. OBESITY AND INSULIN RESISTANCE	18
1.3.1. Obesity	18
1.3.2. Insulin Resistance	19
1.4. THE ENDOCANNABINOID SYSTEM	22
1.4.1. Isolation of Delta-9-Tetrahydrocannabinol (Δ^9 -THC) and the receptors for Endocannabinoids	22
1.4.2. The Cannabinoid Receptors.....	22
1.4.3. Other Receptors for Cannabinoids	26
1.4.4. Cannabinoid Receptor Agonists and Inverse Agonists	26
1.4.5. Levels of Endocannabinoids in Unstimulated Tissues and Cells	30
1.4.6. Central Effects of Endocannabinoids on Energy Metabolism.....	31
1.4.7. Peripheral Effects of Endocannabinoids on Energy Metabolism.....	32
1.4.8. Effects of Endocannabinoids on Energy Metabolism During Onset of Obesity....	39
1.5. TRANSIENT RECEPTOR POTENTIAL CHANNEL-VANILLOID SUB-FAMILY MEMBER 1 (TRPV1)	44
1.5.1. Isolation and Roles of TRPV1.....	44

1.5.2. TRPV1, Obesity and Insulin Resistance	47
1.5.3. TRPV1 and the Endocannabinoid System.....	48
1.6. AIMS AND HYPOTHESES.....	50
MATERIALS AND METHODS	51
2.1. CELL CULTURE	51
2.1.1. Collection of Human Tissue	51
2.1.2. Primary Human Skeletal Muscle Cell Culture.....	52
2.1.3. Collection of Rodent Skeletal Muscle	54
2.1.4. Rodent Myogenic Cell Culture (L6)	54
2.2. mRNA ANALYSIS.....	55
2.2.1. RNA Extraction.....	55
2.2.2. Reverse Transcription of RNA.....	56
2.2.3. Reverse Transcription Polymerase Chain Reaction (RT-PCR).....	57
2.2.4. 'Real Time' RT-PCR	58
2.2.5. Primer Sequences.....	59
2.3. GLUCOSE UPTAKE	63
2.3.1. Human Primary Skeletal Muscle 2-[³ H]deoxy-D-glucose Uptake	63
2.3.2. L6 Insulin-Stimulated 2-[³ H]deoxy-D-glucose Uptake	64
2.4. WESTERN BLOT	66
2.4.1. Collection of Protein	66
2.4.2. Western Blot Protocol	66
2.5. TRPV1 KNOCKOUT STUDIES	68
2.5.1. Animals.....	68
2.5.2. Intraperitoneal glucose tolerance tests.....	68
2.6. STATISTICAL ANALYSIS	70
SR141716, A SELECTIVE CB₁ INVERSE AGONIST, INCREASES BASAL GLUCOSE UPTAKE IN HUMAN SKELETAL MUSCLE MYOTUBES DERIVED FROM OBESE PATIENTS	71
3.1. SUMMARY	71
3.2. INTRODUCTION.....	73
3.3. MATERIALS AND METHODS.....	77
3.3.1. Human Primary Skeletal Muscle Cell Culture.....	77
3.3.2. Experimental Protocols.....	79

3.3.3. Basal Glucose Uptake.....	79
3.3.4. RNA Extraction and 'Real Time' RT-PCR	80
3.3.5. Western Blot.....	80
3.3.6. Statistical Analyses	81
3.4. RESULTS.....	82
3.4.1. Basal Glucose Uptake.....	82
3.4.2. mRNA Expression	84
3.4.3. Phosphorylation of AMPK α and MEK1/2	88
3.5. DISCUSSION.....	92
ENDOCANNABINOID RECEPTOR EXPRESSION IN SKELETAL MUSCLE.....	98
4.1. SUMMARY.....	98
4.2. INTRODUCTION.....	99
4.3. MATERIALS AND METHODS.....	101
4.3.1. Human and Rodent Tissue and Cell Culture.....	101
4.3.2. RNA Extraction and RT-PCR	101
4.4. RESULTS.....	102
4.5. DISCUSSION.....	108
ENDOCANNABINOIDS ENHANCE INSULIN-STIMULATED GLUCOSE UPTAKE IN RODENT L6 SKELETAL MUSCLE MYOTUBES; AN EFFECT MEDIATED BY CB₁, CB₂ AND TRPV1	112
5.1. SUMMARY.....	112
5.2. INTRODUCTION.....	114
5.3. MATERIALS AND METHODS.....	116
5.3.1. Chemicals.....	116
5.3.2. Cell Culture (L6).....	116
5.3.3. Experimental Protocol	116
5.3.4. Basal and Insulin-Stimulated 2-[³ H]deoxy-D-glucose Uptake	118
5.3.5. Statistical Analysis.....	118
5.4. RESULTS.....	119
5.4.1. Effect of Endocannabinoids on Basal and Insulin-Stimulated Glucose Uptake in Skeletal Muscle	119
5.4.2. Effect of Chronic Inhibition of the Receptors for Endocannabinoids on Basal and Insulin-Stimulated Glucose Uptake in Skeletal Muscle.....	121

5.5. DISCUSSION.....	126
TRPV1 MEDIATES DISCORDANT EFFECTS ON THE REGULATION OF FAT MASS AND GLUCOSE METABOLISM	133
6.1. SUMMARY.....	133
6.2. INTRODUCTION.....	135
6.3. MATERIALS AND METHODS.....	139
6.3.1. Wild-type and TRPV1 ^{-/-} Mice	139
6.3.2. Genotyping of TRPV1 ^{-/-} Mice	139
6.3.3. Intraperitoneal Glucose Tolerance Tests.....	139
6.3.4. TRPV1 and FAAH mRNA content by Fibre-Type in Rodent Skeletal Muscle	140
6.3.5. Statistical Analysis.....	140
6.4. RESULTS.....	141
6.4.1. Genotyping of TRPV1 ^{-/-} Mice	141
6.4.2. Wild-Type and TRPV1 ^{-/-} Mice Body Weight.....	143
6.4.3. Basal Glucose Tolerance in Wild-Type and TRPV1 ^{-/-} Mice.....	146
6.4.4. Effect of High Fat Feeding on Glucose Tolerance in Wild-Type and TRPV1 ^{-/-} Mice	149
6.4.5. TRPV1 and FAAH mRNA content by Fibre-Type in Rodent Skeletal Muscle	153
6.5. DISCUSSION.....	155
6.6. FUTURE DIRECTIONS	159
CONCLUSIONS.....	160
7.1. SUMMARY OF FINDINGS.....	160
7.2. IMPLICATIONS OF FINDINGS.....	169
7.3. LIMITATIONS OF THE STUDIES WITHIN THIS THESIS.....	171
7.4. FUTURE STUDIES.....	172
REFERENCES	173

LIST OF FIGURES AND TABLES

FIGURES

		Page
Figure 1.1	Schematic of cellular glucose transport in skeletal muscle	6
Figure 1.2	Simplified schematic of glucose utilisation in skeletal muscle	9
Figure 1.3	Regulation and function of AMPK in skeletal muscle metabolism	13
Figure 1.4	Regulation and function of PDK4 on skeletal muscle glucose utilisation	17
Figure 1.5	Main effects of CB ₁ on intracellular signalling cascades	24
Figure 1.6	Metabolism of AEA and 2-AG by FAAH and MAGL	28
Figure 1.7	TRPV1 signalling increases intracellular calcium and release of pro-inflammatory neuropeptides	46
Figure 3.1	Glucose uptake in myotubes derived from lean (A) and obese (B) subjects (n=4/group)	83
Figure 3.2	Analysis of PDK4 (A and B) and PGC-1 α (C and D) mRNA in myotubes derived from lean and obese subjects (n=3/group)	86
Figure 3.3	Analysis of AMPK α 1 (A and B) and AMPK α 2 (C and D) mRNA in myotubes derived from lean and obese subjects (n=3/group)	87
Figure 3.4	Representative western blot for the measurement of AMPK α (A) and MEK1/2 (B) protein phosphorylation.	89
Figure 3.5	Ratio of phosphorylated to total protein of AMPK α (A and B) and MEK1/2 (C and D) in myotubes derived from lean and obese subjects (n=4/group)	90
Figure 4.1	Gel electrophoresis of RT-PCR products (CB ₁ and CB ₂)	103

Figure 4.2	Gel electrophoresis of RT-PCR products (FAAH and TRPV1)	106
Figure 5.1	Basal and insulin-stimulated glucose uptake in L6 cell culture in response to AEA (A and B) and 2-AG (C and D)	120
Figure 5.2	Basal and insulin-stimulated glucose uptake in L6 cell culture in response to SR141716 (A), SR144528 (B) and SB366791 (C)	122
Figure 5.3	Endocannabinoid mediated basal and insulin-stimulated glucose uptake in L6 cell culture in response SR141716, SR144528 and SB366791	124
Figure 6.1	Representative sample of TRPV1 genotyping	142
Figure 6.2	Cumulative body weight of wild-type and TRPV1 ^{-/-} mice during 18 weeks of diet on either a standard chow diet (chow) or a high fat diet (HFD) (n=8/group)	144
Figure 6.3	Glucose tolerance in wild-type and TRPV1 ^{-/-} mice at 8 weeks of age	147
Figure 6.4	Effect of high fat feeding on glucose tolerance in wild-type and TRPV1 ^{-/-} mice after 18 weeks	150
Figure 6.5	Analysis of FAAH (A) and TRPV1 (B) mRNA in skeletal muscle from male Wister rats (n=12/group)	154
Figure 7.1	Proposed mechanism of EC signalling to promote glucose uptake in skeletal muscle under normal conditions	165
Figure 7.2	Proposed mechanism of EC signalling to promote glucose uptake in skeletal muscle under obese conditions	166
Figure 7.3	Proposed mechanism of EC signalling to promote glucose uptake in skeletal muscle of TRPV1 ^{-/-} mice	168

TABLES

		Page
Table 1.1	Tissue-Specific Effects of AEA and SR141716 in Obesity	41
Table 1.2	<i>In Vivo</i> Effects of AEA and SR141716 in Obesity	42
Table 2.1	Human Primer Sequences	60
Table 2.2	Rodent Primer Sequences	61
Table 2.3	Genotyping Primer Sequences for TRPV1 ^{-/-} Mice	62
Table 3.1	Subject Characteristics	78
Table 3.2	Basal mRNA Expression of Genes	85
Table 6.1	Basal Glucose Tolerance AUC Values (Arbitrary Units)	148
Table 6.2	AUC Values of the Effect of High Fat Feeding on Glucose Tolerance in Wild-Type and TRPV1 ^{-/-} Mice (Arbitrary Units)	152

THESIS SUMMARY

Obesity is a risk factor for type 2 diabetes mellitus and cardiovascular disease. Obesity, in particular when the fat is predominantly visceral, is associated with insulin resistance and a reduced ability to increase the rate of fat oxidation in response to an increase in dietary fat intake. Skeletal muscle is a primary site for insulin-stimulated glucose uptake. Insulin responsiveness in skeletal muscle is regulated by a number of factors including growth hormone, cortisol, sex steroids, cytokines secreted by inflammatory cells and adipocytes, fatty acids, and fatty acid derivatives such as the endocannabinoids.

The most abundant endocannabinoids, anandamide (AEA) and 2-arachidonoylglycerol (2-AG) are synthesised from arachidonic acid. They have autocrine or paracrine mechanisms of action which are rapidly terminated by cellular uptake and subsequent metabolism by fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) which degrades AEA and 2-AG, respectively. AEA and 2-AG are ligands for the cannabinoid receptor type 1 (CB₁) and the cannabinoid receptor type 2 (CB₂); both are 7 transmembrane domain G-protein coupled receptors. AEA and 2-AG also bind to the transient receptor potential channel-vanilloid sub-family member 1 (TRPV1). TRPV1 is a putative six-transmembrane domain protein with a pore region between segments five and six

and cytoplasmic N and C termini. TRPV1 was initially discovered as a receptor for capsaicin, the main pungent component of hot chilli. Activation of TRPV1 leads to an increase in intracellular calcium either by entry through the plasma membrane or through calcium release of intracellular stores.

Endocannabinoids and their receptors form part of an endogenous system that regulates a number of homeostatic functions, including food intake (appetite and motivation to eat via effects in the hypothalamus and nucleus accumbens shell), the regulation of fat mass and intermediary metabolism. An overactivity of the endocannabinoid system in obesity may serve to maintain fat mass and may also underlie some of the associated metabolic consequences. Several studies have shown that inhibition of CB₁ in obese animal models improved the metabolic profile and reversed the deleterious effects of obesity on metabolism. The majority of this data was based on the effects of endocannabinoids on adipose tissue and liver. The studies that form the basis of this thesis examined the effect of endocannabinoids on glucose uptake and metabolism in skeletal muscle.

It was initially shown that CB₁ inhibition improves basal glucose uptake in primary cultures obtained from obese, but not lean humans. This is consistent with the notion of an “overactive endocannabinoid system” apparent even in the *ex-vivo* system of primary culture (**Chapter 3**). These data could not however all be

explained by the presence of a single type of endocannabinoid receptor in skeletal muscle. In a series of studies messenger RNA for CB₁, CB₂, TRPV1 and the enzyme FAAH was shown to be present in human and rat skeletal muscle biopsies, primary cultures of human skeletal muscle and a rat skeletal muscle cell line (L6) (**Chapter 4**).

Subsequent experiments to determine the effect of endocannabinoids on basal and insulin-stimulated glucose uptake and receptors mediating these effects were performed in L6 cells (**Chapter 5**). Chronic (24 h), but not acute (30 min) exposure to AEA and 2-AG increased insulin-stimulated glucose uptake and the effect of 2-AG was greater than that of AEA. 2-AG was used in subsequent studies. 2-AG-mediated glucose uptake was ameliorated by inhibition of CB₁ (SR141716), CB₂ (SR144528) or TRPV1 (SB366791) with no additional effect when more than one receptor was blocked concurrently. These studies are the first to demonstrate the presence of TRPV1 in skeletal muscle and that it has a role in glucose regulation.

To investigate a role for TRPV1 on glucose metabolism *in vivo*, targeted mutant mice with a deletion of the TRPV1 gene were utilised. The studies described in **Chapter 6** measured glucose tolerance in TRPV1^{-/-} mice in comparison to wild-type mice in response to a standard or high fat diet (HFD) via intraperitoneal glucose tolerance testing. At baseline the TRPV1^{-/-} mice were able to clear a glucose load

more efficiently than their wild-type counterparts. After 18 weeks of high fat feeding, body weight of the wild-type mice increased significantly and glucose tolerance was impaired. In contrast, the TRPV1^{-/-} mice were resistant to diet induced obesity, but their glucose tolerance was similar to that of the wild-type mice. The reason for the discrepancy between adiposity and glucose tolerance is unknown, however, *in vitro* studies describing an effect of endocannabinoids to increase insulin-stimulated glucose uptake via TRPV1 suggests a role for this receptor in the regulation of glucose utilisation. The novel observations relating to TRPV1 offer a new perspective on endocannabinoid mediated effects on peripheral metabolism with potential therapeutic implications. Further studies are required to determine the relationship between the effects of endocannabinoids on peripheral metabolism and the emerging role of TRPV1 in diabetes and obesity.

THESIS DECLARATION

This work contains no material which has been accepted for the award of any other degree or diploma in any university or other institution and to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made in the text. I give consent to this copy of my thesis when deposited in the University of Adelaide Library, being made available for loan and photocopying, subject to the provisions of the Copyright Act 1968. The author acknowledges that copyright of published works contained within this thesis (as listed below) resides with the copyright holders of those works. I also give permission for the digital version of my thesis to be made available on the web, via the University's digital research repository, the Library catalogue, the Australasian Digital Thesis Program (ADTP) and also through web search engines, unless permission has been granted by the University to restrict access for a period of time.

Paul Cavuoto

December 2010

ACKNOWLEDGEMENTS

All of the experiments presented in this thesis were performed at the Discipline of Medicine and Discipline of Surgery, University of Adelaide, Royal Adelaide Hospital. Studies were supported by the Centre of Clinical Research Excellence (CCRE) in Nutritional Physiology, Interventions and Outcomes and by Sanofi Aventis.

To all of the following people, I am indebted for providing advice, guidance, knowledge and support over the course of my research, and during the writing of this thesis. Without these people, the whole enterprise of undertaking a PhD would have been much less successful.

First and foremost, I would like to thank my principle supervisor, Professor Gary Wittert. Gary, the guidance, support and patience you have afforded me over these past few years has been invaluable. There have been many challenges during my candidature which you have helped me to meet head-on and overcome. I have learned so much under your careful watch and improved so much as a scientific researcher.

I am also greatly indebted to my co-supervisors, Dr. Andrew McAinch and Dr. Alena Janovská. Andrew and Alena provided the foundation for all my current *in vitro* and *in vivo* lab skills and techniques. Thank you both for your supervision and

patience, especially during the early stages of my candidature. I now have a broad skill set which I attribute to your help and guidance. I would also like to thank Andrew and Alena for allowing me to use their cell culture and rodent skeletal muscle samples, respectively. Thank you to Associate Professor David Cameron-Smith from Deakin University for kindly providing the L6 cell culture samples. To Ashley Blackshaw and the rest of the Nerve Gut Lab, thank you for providing me with the TRPV1^{-/-} mice and for always helping me whenever I needed it. A very special thank you to Associate Professor Leonie Heilbronn, who has provided me with so much support and guidance with my thesis writing.

I would also like to thank George Hatzinikolas for helping me during my culture experiments and during animal surgeries and for always providing a good laugh when I needed it. Thank you to Lisa Philp and Yan Lam who are/were fellow PhD candidates, you have both helped me immensely with my work and I wish you both all the best in your future endeavours. To Kerry Kristaly and Jane Mudge and many others who have previously been a member of the Wittert team, thank you all for your help and support during my candidature.

I would like to thank the staff at the Discipline of Surgery. To Neville De Young, Eric Smith and Paul Drew, thank you for allowing me the use of your equipment, expertise and advice. To Ginetta Noto, Philip Game, Peter Devitt and Glyn “the Prof” Jamieson, thank you for helping me with the collection of human tissue samples

during surgery. Thank you also to the staff of the Burnside Hospital, Calvary Hospital and Royal Adelaide Hospital for being so accommodating while I was in theatre.

I am greatly indebted to everyone who has ever had a desk in the “cool” PhD office: Ixchel Brennan, Diana Gentilcore, Kylie Lange, Tanya Little, Lisa Philp, Amy Ryan, Radhika Seimon, Kate Smith, Kamilia Tai and Lora Vanis. Thank you all for being such fantastic work colleagues and for providing me with such a positive working environment.

To everyone within the Discipline of Medicine, thank you for all your help and support during my PhD. I would especially like to thank Natalie Luscombe-Marsh for all her guidance, encouragement and for always having an open door when I needed advice. Thank you to Kylie Lange for all her help with the statistical analysis of my data and for teaching me the ropes of SPSS. I would also like to thank all the staff at the Discipline of Surgery and at the IMVS animal house for all the help and support provided during my experiments.

Most importantly, thank you to all my friends and especially my family. You have provided me with such a strong support base and the will to succeed. To my parents, Umberto and Carmelina, thank you so much for your love, encouragement and support. To my grandparents and all my aunties, uncles and cousins, thank you for all your understanding and support during these past few years. To my best

Acknowledgements

mates, Andrew Trotta and Anindya Ferreira, your continuing friendship has been invaluable. To all my friends, especially Saumya Samaraweera, thank you for all your help and support. To Jasper Raj, you have brought stability and happiness to the apartment and even though you are a cat, you are a treasured friend. To Shobhana Nair Sreetharan, your arrival into Australia has enriched both my life and Niva's life. Thank you for being you. Finally to my partner, Niva Nair Sreetharan, your continuing love and support has been a shining light through all the ups and downs of my PhD. We have both taken the hard road and together we got through it all. Thank you, from the bottom of my heart.

PUBLICATIONS ARISING FROM THIS THESIS

PUBLISHED MANUSCRIPTS

Cavuto P, McAinch AJ, Hatzinikolas G, Janovská A, Game P, Wittert GA. *The expression of receptors for endocannabinoids in human and rodent skeletal muscle.* Biochemical and Biophysical Research Communications, 2007, **364**(1): 105-110.

Cavuto P, Wittert GA. *The role of the endocannabinoid system in the regulation of energy expenditure.* Best Practice & Research: Clinical Endocrinology & Metabolism, 2009, **23**(1): 79-86.

MANUSCRIPTS IN PREPARATION

Cavuto P, McAinch AJ, Janovská A, Hatzinikolas G, Lam YY, Cameron-Smith D, Wittert GA. *SR141716, a selective CB1 inverse agonist, increases basal glucose uptake in human skeletal muscle myotubes derived from obese patients.*

Cavuto P, Wittert GA, Janovska A, Lam YY, Hatzinikolas G, Blackshaw LA. *TRPV1 Mediates Discordant Effects on the Regulation of Fat Mass and Glucose Metabolism.*

OTHER MANUSCRIPTS IN PREPARATION

Lam YY, Janovská A, McAinch AJ, Hatzinikolas G, **Cavuto P**, Game P, Wittert GA. *Insulin-stimulated glucose uptake and pathways regulating energy metabolism in skeletal muscle cells: the effects of subcutaneous and visceral fat, and long-chain saturated, n-3 and n-6 polyunsaturated fatty acids.*

PUBLISHED ABSTRACTS

Cavuoto P, McAinch AJ, Hatzinikolas G, Wittert GA. *Effects of cannabinoid receptors on skeletal muscle oxidative pathways*. *Obesity Reviews*, 2006, **7**(supp.2): 130.

Wittert GA, **Cavuoto P**, Hatzinikolas G, Blackshaw LA. *TRPV1 Mediates Discordant Effects on the Regulation of Fat Mass and Glucose Metabolism*. *Diabetes*, 2010, **59**(supp.1A): LB31.

CONFERENCE PRESENTATIONS

ORAL PRESENTATIONS

Cavuto P, McAinch AJ, Janovská A, Hatzinikolas G, Lam YY, Cameron-Smith D, Wittert GA. *The effect of the selective CB1 inverse agonist SR141716 on human skeletal muscle myotubes*. The 2009 Post Graduate Research Expo (Finalist), Faculty of Health Sciences, University of Adelaide, Adelaide, Australia, September 1, 2009.

Cavuto P, McAinch AJ, Janovská A, Hatzinikolas G, Lam YY, Cameron-Smith D, Wittert GA. *The effect of the first selective cb1 blocker rimonabant on human skeletal muscle myotube gene expression*. Centre of Clinical Research Excellence (CCRE) seminar, Discipline of Medicine, University of Adelaide, Adelaide, Australia, November 14, 2007.

Cavuto P, McAinch AJ, Janovská A, Hatzinikolas G, Lam YY, Cameron-Smith D, Wittert GA. *The effect of the first selective CB1 blocker rimonabant on human skeletal muscle myotube gene expression (Hot Topics)*. Australasian Society for the Study of Obesity 16th Annual Scientific Meeting, Canberra, Australia, August 31-September 2, 2007.

POSTER PRESENTATIONS

Wittert GA, **Cavuoto P**, Hatzinikolas G, Blackshaw LA. *TRPV1 mediates discordant effects on the regulation of fat mass and glucose metabolism*. The 70th Scientific Sessions, American Diabetes Association (ADA), Orlando, USA, 25-29 June 2010.

Cavuoto P, McAinch AJ, Janovská A, Hatzinikolas G, Lam YY, Cameron-Smith D, Wittert GA. *The effect of the selective CB1 inverse agonist SR141716 on human skeletal muscle myotubes*. The 2009 Australian Diabetes Society and Australian Diabetes Educators Association (ADS-ADEA) Annual Scientific Meeting, Adelaide, Australia, 26-28 August 2009.

Cavuoto P, Janovská A, Lam YY, Wittert GA. *Endocannabinoids and the regulation of insulin-stimulated glucose uptake in rodent skeletal muscle*. The 2008 Postgraduate Research Expo, Faculty of Health Sciences, University of Adelaide, Adelaide, Australia, 23 July 2008.

Lam YY, McAinch AJ, Janovská A, Hatzinikolas G, **Cavuoto P**, Wittert GA. *An adipose tissue-myotube co-culture system to study nutrient utilisation in skeletal muscle cells*. The 2007 Postgraduate Research Expo, Faculty of Health Sciences, University of Adelaide, Adelaide, Australia, 23 October 2007.

Cavuoto P, McAinch AJ, Janovská A, Hatzinikolas G, Lam YY, Cameron-Smith D, Wittert GA. *The effect of the selective CB1 blocker SR141716 on human skeletal muscle myotubes*. The 2007 Postgraduate Research Expo, Faculty of Health Sciences, University of Adelaide, Adelaide, Australia, 23 October 2007.

Lam YY, McAinch AJ, Janovská A, Hatzinikolas G, **Cavuoto P**, Wittert GA. *An adipose tissue-myotube co-culture system to study nutrient utilisation in skeletal muscle cells*. Australasian Society for the Study of Obesity 16th Annual Scientific Meeting, Canberra, Australia, August 31-September 2, 2007.

McAinch AJ, **Cavuoto P**, Hatzinikolas G, Cameron-Smith D, Wittert GA. *The effect of the selective CB1 antagonist sr141716 on human skeletal muscle myotube gene*

expression. The 4th Asia-Oceania Conference on Obesity, Seoul, Korea, 9-11 February 2007.

LIST OF ABBREVIATIONS

Δ^9-THC	delta-9-tetrahydrocannabinol
2-AG	2-arachidonoylglycerol
ACC	acetyl coenzyme A carboxylase
ACEA	arachidonyl-2'-chloroethylamide hydrate
ADTP	Australasian Digital Thesis Program
AEA	anandamide
AMPK	AMP-activated protein kinase
AUC	area under the curve
BAT	brown adipose tissue
BDNF	brain derived neurotrophic factor
BMI	body mass index
BP	base-pairs
CaMKK	calmodulin-dependent protein kinase kinase
cAMP	cyclic AMP
CB₁	cannabinoid receptor type 1
CB₂	cannabinoid receptor type 2
CGRP	calcitonin-gene-related peptide
CoA	Coenzyme A
CPT-1	carnitine palmitoyltransferase-1
C_T	critical threshold

DAG	diacylglycerol
DOG	deoxy-D-glucose
DRG	dorsal root ganglia
ECM	extra cellular matrix
ECs	endocannabinoids
EDL	extensor digitorum longus
eNOS	endothelial nitric oxide synthase
FAAH	fatty acid amide hydrolase
FA	fatty acid
FAF	fatty acid free
FBS	fetal bovine serum
FFAs	free fatty acids
G-6-P	glucose-6-phosphate
GC-MS	gas chromatography coupled to mass spectrometry
HEK	human embryonic kidney
HFD	high fat diet
HPLC	high pressure liquid chromatography
HS	horse serum
IR	insulin receptor
K_A⁺	A-type potassium
K_{ir}	inwardly rectifying potassium
MAGL	monoacylglycerol lipase

MAPK	mitogen-activated protein kinase
MBH	mediobasal hypothalamus
MEF2C	myocyte enhancer factor 2C
NGF	nerve growth factor
NHS	National Health Survey
NRFs	nuclear respiratory factors
PDC	pyruvate dehydrogenase complex
PDKs	pyruvate dehydrogenase kinases
PDK4	pyruvate dehydrogenase kinase 4
PEA	<i>N</i> -palmitoylethanolamine
PGC-1α	peroxisome proliferator-activated receptor γ coactivator 1 α
PhD	Doctor of Philosophy
PI3K	phosphoinositide 3-kinase
PKA	protein kinase A
PKB	protein kinase B (also known as Akt)
PKC	protein kinase C
PPARγ	peroxisome proliferator-activated receptor γ
PVDF	polyvinylidene difluoride
RT-PCR	reverse transcription polymerase chain reaction
RTX	resiniferatoxin
SF1	steroidogenic factor 1
SOL	soleus

SP	substance P
SREBP-1c	sterol-regulatory element-binding protein-1c
T2DM	type 2 diabetes mellitus
TBS/T	tris-buffered saline/0.1% Tween 20
TG	triglycerides
TRPV1	transient receptor potential channel-vanilloid sub-family member 1
VMH	ventro medial hypothalamus
WHO	World Health Organisation